Vanda Pharmaceuticals

Vanda's business model is fully integrated, covering drug discovery, clinical development, regulatory approval, and commercialization. Revenue is primarily generated from the sales of its main products. The company's commercial portfolio includes HETLIOZ® (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and sleep disturbances in Smith-Magenis Syndrome; Fanapt® (iloperidone) for schizophrenia and bipolar I disorder in adults; and PONVORY® (ponesimod) for relapsing forms of multiple sclerosis, which it acquired the U.S. and Canadian rights for from a Johnson & Johnson company in December 2023.

The company invests significantly in research and development to expand its product pipeline, utilizing genetics and genomics to inform drug discovery and clinical trials. Its pipeline includes tradipitant for gastroparesis and motion sickness, a long-acting injectable version of Fanapt®, and VCA-894A for Charcot-Marie-Tooth disease, among others. Vanda has faced regulatory challenges, including an FDA rejection for tradipitant in gastroparesis in September 2024. As of December 31, 2024, Vanda's annual revenue was reported at $199 million. Keywords: biopharmaceutical, central nervous system disorders, schizophrenia, Non-24-Hour Sleep-Wake Disorder, Fanapt, Hetlioz, drug development, clinical trials, pharmaceutical commercialization, genetics, genomics, Mihael Polymeropoulos, Ponvory, multiple sclerosis, bipolar disorder, Smith-Magenis Syndrome, tradipitant, gastroparesis, motion sickness, orphan drugs, specialty pharmaceuticals, rare diseases